ZAI LAB LIMITED Inventory, Raw Materials, Net of Reserves
ZAI LAB LIMITED (ZLAB) had Inventory, Raw Materials, Net of Reserves of $27.12 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsNetOfReserves · last filed 2026-08-06
- 2026-06-30: Inventory, Raw Materials, Net of Reserves $27.12M.
- 2026-03-31: Inventory, Raw Materials, Net of Reserves $24.25M.
- 2025-12-31: Inventory, Raw Materials, Net of Reserves $23.11M.
- 2025-09-30: Inventory, Raw Materials, Net of Reserves $22.57M.
| Period end | Inventory, Raw Materials, Net of Reserves |
|---|---|
| 2026-06-30 | $27.12M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $24.25M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $23.11M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $22.57M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $21.23M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $15.32M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.40M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $16.11M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $16.68M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $17.66M 10-K · filed 2025-02-27 |
| 2023-09-30 | $22.81M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $19.32M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $20.52M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $19.03M 10-K · filed 2024-02-27 |
| 2021-12-31 | $13.23M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |